Inauhzin

Catalog No.S6744 Batch:S674401

Print

Technical Data

Formula

C25H19N5OS2

Molecular Weight 469.58 CAS No. 309271-94-1
Solubility (25°C)* In vitro DMSO 94 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Inauhzin is a cell-permeable SIRT1 inhibitor with an IC50 of 0.7-2 μM and reactivates p53 by inhibiting SIRT1 deacetylation activity.
Targets
SIRT1 [2] p53 [1]
In vitro

Inauhzin (INZ) is a potent p53 activator and mediates p53-dependent cytotoxicity. INZ inhibits cell proliferation by triggering both apoptosis and senescence in p53-containning cells, though it predominantly induces p53-dependent apoptosis. INZ is able to prevent p53 from MDM2-mediated ubiquitylation and proteasomal degradation and protects p53 without either directly inhibiting MDM2 activity towards p53 or interfering with MDMX/MDM2–p53 interaction. INZ induces acetylation of p53, but not tubulin, in cells[1]. Inauhzin is a (sub)micromolar SIRT1i selective over SIRT2/3[2].

In vivo

Inauhzin (INZ) has good tumour tissue penetration and is able to inhibit tumour growth by inducing p53[1].

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    human lung cancer H460, A549, H1299, colon cancer HCT116, HT29, osteosarcoma U2OS and SJSA, breast cancer MCF7, ovarian cancer A2780, IGROV1 and SKOV3 and glioma U87 and U373 cells, as well as human embryonic fibroblast WI-38 and normal human fibroblast (NHF) cells

  • Concentrations

    0-10 μM

  • Incubation Time

    18 h

  • Method

    --

Animal Study:

[1]

  • Animal Models

    SCID mice with H460 xenograft tumours

  • Dosages

    30 mg/kg

  • Administration

    IP

Selleck's Inauhzin has been cited by 2 publications

Effects of Hst3p inhibition in <i>Candida albicans</i>: a genome-wide H3K56 acetylation analysis [ Front Cell Infect Microbiol, 2022, 12:1031814] PubMed: 36389164
SIRT1 inhibitors mitigate radiation-induced GI syndrome by enhancing intestinal-stem-cell survival [ Cancer Lett, 2020, 501:20-30] PubMed: 33359449

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.